<< Read Full Article
<< Read Full Article
Once again, health stocks were down in line with the broader markets, and with light news flow.
Big biotechs Celgene(CELG Quote) and Gilead(GILD Quote) were down 3.4% and 2.4%, helping to hold down the biotech indices. The Nasdaq and Amex indices were off by 1.6% and 1.2%, respectively.
One mover, Amylin(AMLN Quote) fell another $1.66, or 5.6%, to $28.10, after falling some 16% a day prior. Stanford Research downgraded Amylin to hold from buy, keeping a price target of $33, a day after regulators warned of two deaths possibly related to the diabetes drug Byetta, which Amylin is developing with Eli Lilly(LLY Quote). ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
Connect with TheStreet